Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

As it can be seen that FBS, TG, TC, LDL, AST, and ALT have a down slope trend, which statistics showed significant changes in some of them; however, other factors like iron, ferritin, vitamin D, and vitamin B12 had been decreased at first and increased afterwards and none of them were significant statistically.

Source: 3. Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

25 patients were put in group 1 (BMI = 40 to 45 kg/m2) and 25 patients in group 2 (BMI = 45 to 50 kg/m2).

Source: Abstract.

This is a prospective cross-sectional study based on 50 patients admitted to our university hospital for MGB/OAGB in 2016 to 18.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

The Early Results of the Laparoscopic Mini-Gastric Bypass/One Anastomosis Gastric Bypass on Patients with Different Body Mass Index

Cross-sectional study · Journal of Obesity · 2020

Original publication title

The Early Results of the Laparoscopic Mini-Gastric Bypass/One Anastomosis Gastric Bypass on Patients with Different Body Mass Index

Mohsen Mahmoudieh; Behrouz Keleidari; Naser Afshin; Masoud Sayadi Shahraki; Shahab Shahabi Shahmiri; Erfan Sheikhbahaei; Hamid Melali

Copyright © 2020 Mohsen Mahmoudieh et al.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

We found that 180-cm intestinal bypass length can make significant changes in weight and BMI in both groups of patients. Glycolipid changes were acceptable in both groups.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Obesity is among the newest health matters that human beings are struggling with today. This condition is increasingly developing in both developed and developing countries. Urbanization, sedentary lifestyle, and dietary changes are factors that have led to a growing rate of obesity [1].

Obesity has a variety of complications causing lower life expectancy including metabolic syndrome, hypertension, insulin resistance, type-2 diabetes mellitus, cardiovascular diseases, osteoarthritis, low back pain, and increased risk of malignancy. In addition, obese people are struggling with decreased self-esteem as they are not satisfied of their appearance leading to depression and reluctance of participation in social activities [2Not reported5].

Bariatric surgery is the most effective treatment for severe obesity. This surgical procedure causes persistent weight loss, modulates complications of obesity, and increases quality of life and eventually patients' life expectancy [6].

Variety of bariatric surgeries are being performed now. Perhaps, the most popular one is Roux-en-Y gastric bypass (RYGB). Recently, it has been confirmed that the laparoscopic mini-gastric bypass/one anastomosis gastric bypass (MGB/OAGB) as an easier technique of gastric bypass is even more effective than the classic technique, RYGB [7, 8]. The RYGB has two limbs: alimentary or Roux limb and biliopancreatic limb. The MGB/OAGB has only one gastrojejunal anastomosis, which is called the biliopancreatic limb as well.

Previous studies in the RYGB field have presented that increased length of the biliopancreatic arm instead of the alimentary limb can lead to more weight reduction [9]. On the contrary, studies have shown that the total small intestine length is different in patients and biliopancreatic limb length is important to avoid complications such as malabsorption or malnutrition and to achieve more weight loss postoperatively [8Not reported10]. In this term, different studies have assessed various lengths of the biliopancreatic arm based on small intestine length or patients' body mass index (BMI).

Although studies have presented valuable results, their presentations are controversial and researchers have not declared unanimous results [11Not reported14].

Based on the importance of selecting the best technique of gastric bypass surgery, preventing secondary malabsorption and metabolic complications, and due to controversial findings of previous studies, we aimed to assess short-term metabolic and nutritional effect of MGB/OAGB with 180-centimeter (cm) intestinal bypass length in patients with a BMI of 40 to 45 and 45 to 50 kg/m2.

Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction

Study methods

What methods does the paper describe?

This is a prospective cross-sectional study based on 50 patients admitted to our university hospital for MGB/OAGB in 2016 to 18. Approximately, 300 total bariatric surgeries are performed in our center every year, from which, 50% of them are MGB/OAGB surgery.

Inclusion criteria were age between 25 and 65 years with BMI ≥40 kg/m2 without any obesity-related comorbidities (e.g., diabetes mellitus, hypertension, and obstructive sleep apnea), consent declaration for participation in this study, patients' ability to tolerate laparoscopic surgery, and lack of laparotomy history.

Exclusion criteria were previous history of any bariatric surgery (e.g., gastric banding, balloon gastroplasty, or other methods), patients' unwillingness or decision change not to participate in the study, having any positive medical history for gastroesophageal reflux disease, diabetes mellitus, hypertension, thyroid, respiratory, kidney, and liver failure, and failure to follow recommended diet supplementation after MGB/OAGB.

Consent forms for participating and all-needed information about the study were given to patients prior to the surgery. This study was conducted after receiving its approval from medical ethics in the research department of our university (registration number: IR.MUI.MED.REC.1398.131).

From our extensive referral for bariatric surgery and after reviewing inclusion and exclusion criteria for all of the patients, we included 50 patients for this research. All patients were allocated into two groups according to their preoperative BMI (40 to 45 and 45 to 50 kg/m2). All patients were supposed to undergo MGB/OAGB with an intestine length bypass of 180 cm [14]. 25 patients were put in group 1 (40 to 45 kg/m2), and 25 patients were put in group 2 (45 to 50 kg/m2).

Essential demographic information including gender, height, first BMI, and laboratory results including fasting blood sugar (FBS), triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), serum iron (Fe), ferritin, total iron-binding capacity (TIBC), 25-OH vitamin D, vitamin B12, international normalized ratio (INR), albumin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were obtained preoperatively. Weight loss, BMI, and abovementioned laboratory data were reassessed in 15, 30, 90, and 180 days postoperatively.

All data were analyzed using IBM SPSS version 23.0 (Chicago, United States). Qualitative variables are expressed as number of patients and percentages. Quantitative variables are expressed as mean and standard deviation (SD). The Kolmogorov: Smirnov test was used to check the normal distribution of the variables. If they were normally distributed, the t-test and chi-square were used and if not, the Mann: Whitney and Wilcoxon tests were used. ANOVA and ANOVA with repeated measures were used to compare the results of each variable between more than two groups. P value <0.05 was considered significant.

2.1. Surgical Protocol

Under general anesthesia, the patient was put in the supine leg splitting position. A nasogastric tube and Foley catheter were inserted. A 150-millimeter (mm) Veress needle was placed in the left subcostal location, and pneumoperitoneum was established using carbon dioxide (CO2) to a maximum pressure of 15 millimeter mercury (mmHg). An 11-mm optical viewing trocar was inserted 15 to 20 cm below the xiphoid process to the left of the midline. The other laparoscopic ports were inserted under direct vision.

The 12-mm right-handed working port was placed in the left midclavicular line, while the 5-mm left-handed working port was placed in the right midclavicular line. One 5-mm port was placed in the epigastrium for retracting the left lobe of the liver. Another 5-mm port was inserted in the left anterior axillary line at the level of the camera port. A narrow and long, approximately, 30 to 40 milliliter (ml) gastric pouch was created just below the crow's foot over a 32 French orogastric tube by four or five 60-mm Endo-GIA Tristaple purple loads (Covidien®/Medtronic).

The gastrojejunostomy anastomosis was created 180 cm from the Treitz ligament with one 45-mm Endo-GIA Tristaple purple load (Covidien®/Medtronic) and was sutured with 2/0 Prolene twice to make sure there will not be any leak from the anastomosis site. After the surgery, all of the patients were sent to the recovery room and when they become conscious, they were sent to the surgery ward. All of the patients were discharged after 2 days of hospitalization if they did not face any early postoperative complications (e.g., peritonitis, leak from the anastomosis, bleeding, and surgical site infection.).

We put all of our patients on full supplementation protocol as follows: first month, daily 10 ml of Sanostol® multivitamin syrup, and after that, until one year after the surgery, we recommended daily Pharmaton® multivitamin capsules.

Source: 2. Methods and Materials Source: 2. Methods and Materials Source: 2. Methods and Materials Source: 2. Methods and Materials Source: 2. Methods and Materials Source: 2. Methods and Materials Source: 2. Methods and Materials Source: 2. Methods and Materials

Discussion

Bariatric surgery as the absolute method of achieving weight loss in those with severe obesity is the favorable procedure used by surgeons. In this matter, a variety of techniques and their debatable concepts have been reviewed and studied to find the best technique of surgery to obtain the best outcomes and the least adverse effects [15].

The other issue about bariatric surgery is the intestinal bypassed length that causes fewer complications such as malabsorption and also acceptable weight loss. Studies have recommended different formulas for that [12Not reported16].

In the current study, we aimed to compare whether more obese patients need longer intestinal bypass length or 180 cm which is a widely used and confirmed intestinal bypass length that works for them too according to their nutritional, metabolic, and weight loss changes following MGB/OAGB. Thus, two comparable groups with a BMI of 40 to 45 and 45 to 50 kg/m2 each containing 25 cases were compared from baseline.

Based on our findings, both groups lost their weight, BMI, and excess weight significantly. According to graphs' slope of these weight-associated variables, both groups had the same slope angle although group 2 had a higher starting point, but as our results showed, both groups had successful and progressive trend in their weight and BMI loss. As it can be seen in Table 1, after 6 months, both groups achieved BMI <35 kg/m2. However, %EWL was higher in patients with lower preoperative BMI level and it can be explained through the EWL formula and its instinct, and patients with higher BMI had more weight to lose in a specific amount of time; therefore, using this indicator is not representative of all changes in weight correctly and completely.

Group 1 patients achieved a mean %EWL of 60.51% 6 months after the surgery; however, group 2, which had higher BMI and higher excess weight, achieved losing 46.64% of their weight during this time by the 180 cm intestinal anastomosis.

In a study conducted by Mahawar et al., they presented that a bypass length of 100 to 200 cm has acceptable outcomes and few possible complications such as malabsorption [16], while in a study conducted by Carbajo et al., they assessed patients who had undergone MGB/OAGB with 250 to 300 cm bypass length and found malabsorption in 1.1% of them that was compatible with prevalence of protein malabsorption presented in other studies [14]. In a study conducted by Lee et al., they compared outcomes of MBG/OAGB surgery in which bypassed length was chosen based on patients' BMI.

In their study, bypassed limb was 150 cm, 250 cm, and 350 cm for those with a BMI of less than 40, 40 to 50, and over 50 kg/m2, respectively. BMI reduction in their patients were 10.7, 15.5, and 23.3, respectively. In general, they concluded that decision on length of the limb should be made based on BMI. In addition, they presented that for those with lower BMI, choosing the appropriate limb length is more serious [13].

Other variables including metabolic and nutritional factors were assessed among two groups as well with intervals of three and six months after the surgery. In general, based on Table 2, we found that metabolic factors tend to change in an acceptable manner, such as decrease of TG, TC, LDL, FBS, and liver enzymes. It is reasonable that patients with higher BMI have higher levels of TG, TC, LDL, and FBS at the baseline, but both groups had progressive declined slope.

Bariatric surgeries reported controversial results on levels of liver enzymes, in which some of them mentioned these surgeries can deteriorate the liver function; however, others suggested that as the weight decreases, the grade of fatty liver decreases and they can cause improvement in the liver function tests. According to the baseline levels, other factors including HDL, serum iron, ferritin, vitamin D, and vitamin B12 were simultaneously decreased in 3 months and then increased after 6 months, and they could be due to postoperative supplement use.

Those changes were not statistically significant between both groups. It should be noted that HDL, which is the antiatherosclerotic lipid, was decreased after the surgery and it is an unexplained, unusual, and unfavorable change, which needed further evaluations.

The study by Rutledge and Walsh presented that gastric ulcer and iron deficiency anemia were the most prevalent and significant postoperative complications in their patients [17]. In our study, serum iron, ferritin, and vitamin B12, which are important indicators of intestinal absorption, were changed in the same way all together after 3 and 6 months.

The other study conducted by Lee et al. assessed serum glucose changes among obese people with type-2 diabetes mellitus. They found that patients with lower BMI had significantly lower liver enzymes and C-peptide preoperatively. In addition, they found that patients lipid profile and FBS returned to normal ranges in approximately 90% of the patients, but these changes were not significantly different among those with a BMI of less than 35 or more than 35 kg/m2 [18].

In a study in 2015, sleeve gastrectomy was compared with MGB/OAGB regarding lipid profile. They presented that although in 3: and 6-month follow-up, lipid profile changes to normal ranges were higher in MBG/OAGB, but after one year, both techniques had similar outcomes [19]. Other studies in this regard have assessed other techniques of bariatric surgery except MGB/OAGB, but outcomes of all studies are unanimous about positive effects of bariatric surgery on the glycolipid profile. In addition, most of the studies are in favor of bypass techniques in comparison to techniques with restrictive approach (e.g., sleeve gastrectomy) [20Not reported22].

To resolve our limitations, we suggest researchers to evaluate each single anastomosis length between two different groups of patients and different intestinal bypass length for patients with the same BMI to reach to a consensus for choosing appropriate intestinal bypass length for patients with different BMI category. Furthermore, larger sample size, randomized controlled trials, and longer postoperative follow-up can decrease the biases of choosing the patients and evaluating the results of bariatric surgery in the long term.

Table 1

Weight, BMI, and excess weight loss changes trend following 6: month follow-up after the laparoscopic one anastomosis gastric bypass.

VariablesBMI groups (kg/m2)Baseline15 days30 days3 months6 months P 1 value P 2 value
Weight, kg (mean ± SD)40 to 45 (n = 25)113.80 ± 8.65106.88 ± 9.02101.72 ± 7.9291.20 ± 8.2081.04 ± 7.71<0.0010.001
45 to 50 (n = 25)132.56 ± 11.86125.68 ± 10.11120.64 ± 9.88109.72 ± 11.4395.96 ± 11.53<0.001
BMI, kg/m2 (mean ± SD)40 to 45 (n = 25)41.53 ± 1.4437.50 ± 7.1637.15 ± 1.6433.25 ± 1.9429.44 ± 2.42<0.0010.007
45 to 50 (n = 25)48.36 ± 2.2845.88 ± 2.4844.03 ± 2.2639.96 ± 2.2234.89 ± 1.82<0.001
Excess weight loss (%)40 to 45 (n = 25)Not reported14.79 ± 4.7923.04 ± 5.7344.24 ± 12.9260.51 ± 24.26<0.0010.007
45 to 50 (n = 25)Not reported10.77 ± 4.1115.45 ± 6.0629.12 ± 15.2246.64 ± 19.04<0.001

P 1 value is the mean differences of each variable in each group data during the time and was calculated using ANOVA with repeated measures. P2 value is the comparison of both the groups for each variable in multiple measures and was calculated with ANOVA.

Table 2

Metabolic and nutritional state results of each BMI group from baseline to 6 months after the laparoscopic one anastomosis gastric bypass.

Variables (mean ± SD)BMI groups (kg/m2)Normal laboratory reference rangeBaseline (n = 50)3 months (n = 50)6 months (n = 50) P 1 value P 2 value
TG (mg/dL)40 to 4535 to 200127.72 ± 51.58119.32 ± 39.13103.92 ± 42.797<0.0010.02∗
45 to 50183.00 ± 71.44162.80 ± 68.30137.88 ± 65.63<0.001
TC (mg/dL)40 to 45Normal: <200
Borderline: 200 to 240
High risk: 240 to 400
Very high risk: >400
181.36 ± 37.50160.24 ± 33.69150.84 ± 22.99<0.0010.03∗
45 to 50209.08 ± 42.75174.04 ± 21.13156.60 ± 21.90<0.001
HDL (mg/dL)40 to 45Men: >35
Women: >45
Desirable value: 40 to 60
Protect against CHD: >60
High risk for CHD: <20
47.32 ± 9.7742.80 ± 5.1744.40 ± 7.460.920.14
45 to 5054.08 ± 14.3249.16 ± 10.5245.52 ± 6.130.73
LDL (mg/dL)40 to 45Desirable: <130
Borderline: 130 to 160
High risk: >160
108.28 ± 32.4699.32 ± 21.3992.52 ± 16.870.440.59
45 to 50117.20 ± 25.46109.64 ± 14.6997.60 ± 14.500.29
Fe (mcg/dL)40 to 4560 to 15087.88 ± 8.8577.48 ± 21.7581.64 ± 30.130.950.40
45 to 5092.08 ± 15.3481.36 ± 12.4189.08 ± 18.090.12
Ferritin (ng/mL)40 to 4520 to 20065.20 ± 15.9757.64 ± 26.6659.20 ± 17.840.700.13
45 to 5065.08 ± 20.8862.18 ± 23.2964.68 ± 48.860.47
TIBC (mcg/dL)40 to 45240 to 450257.76 ± 52.26292.2 ± 47.57304.56 ± 52.390.150.054
45 to 50280.88 ± 75.94285.92 ± 65.66298.40 ± 75.310.55
Vit B12 (pg/mL)40 to 45200 to 900349.64 ± 112.06342.68 ± 126.76354.52 ± 107.180.440.03∗
45 to 50300.56 ± 63.82310.52 ± 71.25308.60 ± 63.680.53
Vit D (ng/mL)40 to 45Severe deficient: <10
Deficient: 10 to 30
Optimal level: 31 to 80
High normal: 91 to 99
Overdose: 100 to 150
Toxic: >150
40.20 ± 4.9336.77 ± 5.8937.80 ± 6.300.570.99
45 to 5038.13 ± 3.8835.82 ± 6.5035.78 ± 9.860.64
FBS (mg/dL)40 to 45Normal: <100
Prediabetes: 100 to 125
Diabetes: >125
96.60 ± 10.4285.72 ± 8.4482.12 ± 6.610.02∗0.21
45 to 50103.72 ± 15.6593.56 ± 11.4184.76 ± 7.940.03∗
INR40 to 45<1.51.08 ± 0.111.10 ± 0.071.11 ± 0.060.430.53
45 to 501.14 ± 0.141.12 ± 0.111.14 ± 0.090.33
Alb (g/dL)40 to 453.5 to 5.54.47 ± 0.244.35 ± 0.314.29 ± 0.280.940.69
45 to 504.54 ± 0.204.40 ± 0.194.31 ± 0.190.72
AST (IU/L)40 to 45<4021.48 ± 5.3518.28 ± 3.3116.84 ± 3.140.600.61
45 to 5023.16 ± 5.2419.64 ± 2.9718.16 ± 3.680.57
ALT (IU/L)40 to 45Male: <40
Female: <30
25.60 ± 6.8220.00 ± 4.9716.92 ± 3.660.430.39
45 to 5025.56 ± 8.6420.88 ± 5.3418.72 ± 4.050.38
ALP (IU/L)40 to 45Female: 64 to 306
Male: 80 to 306
198.28 ± 18.32192.20 ± 17.40194.64 ± 17.920.290.47
45 to 50187.20 ± 27.43184.04 ± 26.81195.24 ± 19.530.66

TG, triglyceride; HDL, high-density lipoprotein; CHD, coronary high disease; LDL, low-density lipoprotein; TC, total cholesterol, Fe, iron; TIBC, total iron-binding capacity; Vit, vitamin; FBS, fasting blood glucose; INR, international normalized ratio; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; g: gram; mg: milligrams; ng: nanograms; mcg: micrograms; pg: picograms; L: liter; dL: deciliter; mL: milliliter; IU: international unit. P1 value is the mean differences of each variable in each group data during the time and was calculated using ANOVA with repeated measures. P2 value is the comparison of both the groups for each variable in multiple measures and was calculated with ANOVA. ∗Indicates significant P value.

Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion

Results

Our patients' mean age was 45 ± 8.36 years (range: 36 to 55) in group 1 and 46 ± 5.49 years in group 2 (range: 35 to 58) (P=0.15). 24% and 40% of groups 1 and 2 were male, respectively (P=0.22). Mean height of group 1 was 165.44 ± 4.98 cm (range: 150 to 175) and for the other group was 165.64 ± 8.45 cm (range: 150 to 175) (P=0.58). Table 1 presents patients' body weight, BMI, and excess weight loss (EWL) in different phases following MGB/OAGB.

Based on Table 1, all mentioned variables changed significantly in the two groups. Patients in groups 1 and 2 achieved %EWL of 60.51% and 46.64% after 6 months, respectively.

Table 2 presents laboratory factors and their changes in 3-month and 6-month periods after the surgery. As it can be seen that FBS, TG, TC, LDL, AST, and ALT have a down slope trend, which statistics showed significant changes in some of them; however, other factors like iron, ferritin, vitamin D, and vitamin B12 had been decreased at first and increased afterwards and none of them were significant statistically. None of our patients faced early postoperative complications. During the 6-month follow-up, none of our patients needed hospital admission for late complications or any reoperations.

All of the data will be available for secondary analysis in necessary cases from the corresponding author through email address.

Table 1

Weight, BMI, and excess weight loss changes trend following 6: month follow-up after the laparoscopic one anastomosis gastric bypass.

VariablesBMI groups (kg/m2)Baseline15 days30 days3 months6 months P 1 value P 2 value
Weight, kg (mean ± SD)40 to 45 (n = 25)113.80 ± 8.65106.88 ± 9.02101.72 ± 7.9291.20 ± 8.2081.04 ± 7.71<0.0010.001
45 to 50 (n = 25)132.56 ± 11.86125.68 ± 10.11120.64 ± 9.88109.72 ± 11.4395.96 ± 11.53<0.001
BMI, kg/m2 (mean ± SD)40 to 45 (n = 25)41.53 ± 1.4437.50 ± 7.1637.15 ± 1.6433.25 ± 1.9429.44 ± 2.42<0.0010.007
45 to 50 (n = 25)48.36 ± 2.2845.88 ± 2.4844.03 ± 2.2639.96 ± 2.2234.89 ± 1.82<0.001
Excess weight loss (%)40 to 45 (n = 25)Not reported14.79 ± 4.7923.04 ± 5.7344.24 ± 12.9260.51 ± 24.26<0.0010.007
45 to 50 (n = 25)Not reported10.77 ± 4.1115.45 ± 6.0629.12 ± 15.2246.64 ± 19.04<0.001

P 1 value is the mean differences of each variable in each group data during the time and was calculated using ANOVA with repeated measures. P2 value is the comparison of both the groups for each variable in multiple measures and was calculated with ANOVA.

Table 2

Metabolic and nutritional state results of each BMI group from baseline to 6 months after the laparoscopic one anastomosis gastric bypass.

Variables (mean ± SD)BMI groups (kg/m2)Normal laboratory reference rangeBaseline (n = 50)3 months (n = 50)6 months (n = 50) P 1 value P 2 value
TG (mg/dL)40 to 4535 to 200127.72 ± 51.58119.32 ± 39.13103.92 ± 42.797<0.0010.02∗
45 to 50183.00 ± 71.44162.80 ± 68.30137.88 ± 65.63<0.001
TC (mg/dL)40 to 45Normal: <200
Borderline: 200 to 240
High risk: 240 to 400
Very high risk: >400
181.36 ± 37.50160.24 ± 33.69150.84 ± 22.99<0.0010.03∗
45 to 50209.08 ± 42.75174.04 ± 21.13156.60 ± 21.90<0.001
HDL (mg/dL)40 to 45Men: >35
Women: >45
Desirable value: 40 to 60
Protect against CHD: >60
High risk for CHD: <20
47.32 ± 9.7742.80 ± 5.1744.40 ± 7.460.920.14
45 to 5054.08 ± 14.3249.16 ± 10.5245.52 ± 6.130.73
LDL (mg/dL)40 to 45Desirable: <130
Borderline: 130 to 160
High risk: >160
108.28 ± 32.4699.32 ± 21.3992.52 ± 16.870.440.59
45 to 50117.20 ± 25.46109.64 ± 14.6997.60 ± 14.500.29
Fe (mcg/dL)40 to 4560 to 15087.88 ± 8.8577.48 ± 21.7581.64 ± 30.130.950.40
45 to 5092.08 ± 15.3481.36 ± 12.4189.08 ± 18.090.12
Ferritin (ng/mL)40 to 4520 to 20065.20 ± 15.9757.64 ± 26.6659.20 ± 17.840.700.13
45 to 5065.08 ± 20.8862.18 ± 23.2964.68 ± 48.860.47
TIBC (mcg/dL)40 to 45240 to 450257.76 ± 52.26292.2 ± 47.57304.56 ± 52.390.150.054
45 to 50280.88 ± 75.94285.92 ± 65.66298.40 ± 75.310.55
Vit B12 (pg/mL)40 to 45200 to 900349.64 ± 112.06342.68 ± 126.76354.52 ± 107.180.440.03∗
45 to 50300.56 ± 63.82310.52 ± 71.25308.60 ± 63.680.53
Vit D (ng/mL)40 to 45Severe deficient: <10
Deficient: 10 to 30
Optimal level: 31 to 80
High normal: 91 to 99
Overdose: 100 to 150
Toxic: >150
40.20 ± 4.9336.77 ± 5.8937.80 ± 6.300.570.99
45 to 5038.13 ± 3.8835.82 ± 6.5035.78 ± 9.860.64
FBS (mg/dL)40 to 45Normal: <100
Prediabetes: 100 to 125
Diabetes: >125
96.60 ± 10.4285.72 ± 8.4482.12 ± 6.610.02∗0.21
45 to 50103.72 ± 15.6593.56 ± 11.4184.76 ± 7.940.03∗
INR40 to 45<1.51.08 ± 0.111.10 ± 0.071.11 ± 0.060.430.53
45 to 501.14 ± 0.141.12 ± 0.111.14 ± 0.090.33
Alb (g/dL)40 to 453.5 to 5.54.47 ± 0.244.35 ± 0.314.29 ± 0.280.940.69
45 to 504.54 ± 0.204.40 ± 0.194.31 ± 0.190.72
AST (IU/L)40 to 45<4021.48 ± 5.3518.28 ± 3.3116.84 ± 3.140.600.61
45 to 5023.16 ± 5.2419.64 ± 2.9718.16 ± 3.680.57
ALT (IU/L)40 to 45Male: <40
Female: <30
25.60 ± 6.8220.00 ± 4.9716.92 ± 3.660.430.39
45 to 5025.56 ± 8.6420.88 ± 5.3418.72 ± 4.050.38
ALP (IU/L)40 to 45Female: 64 to 306
Male: 80 to 306
198.28 ± 18.32192.20 ± 17.40194.64 ± 17.920.290.47
45 to 50187.20 ± 27.43184.04 ± 26.81195.24 ± 19.530.66

TG, triglyceride; HDL, high-density lipoprotein; CHD, coronary high disease; LDL, low-density lipoprotein; TC, total cholesterol, Fe, iron; TIBC, total iron-binding capacity; Vit, vitamin; FBS, fasting blood glucose; INR, international normalized ratio; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; g: gram; mg: milligrams; ng: nanograms; mcg: micrograms; pg: picograms; L: liter; dL: deciliter; mL: milliliter; IU: international unit. P1 value is the mean differences of each variable in each group data during the time and was calculated using ANOVA with repeated measures. P2 value is the comparison of both the groups for each variable in multiple measures and was calculated with ANOVA. ∗Indicates significant P value.

Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results

Conclusions

We found that 180-cm intestinal bypass length can make significant changes in weight and BMI in both groups of patients. Glycolipid changes were acceptable in both groups.

Source: 5. Conclusions
Authors’ abstract

Introduction. Obesity is among the newest health matters that human beings are struggling with. Length of bypassed intestine is important in achievement of most weight loss and least nutritional and absorptive disorders. This study has aimed to assess short-term metabolic and nutritional effects of laparoscopic mini-gastric bypass/one anastomosis gastric bypass (MGB/OAGB) with a loop bypass length of 180 centimeters (cm) and compare these factors among patients with a body mass index (BMI) of 40 to 45 and 45 to 50 kilograms per square meter (kg/m2).

Methods

25 patients were put in group 1 (BMI = 40 to 45 kg/m2) and 25 patients in group 2 (BMI = 45 to 50 kg/m2). Patients' BMI, postoperative weight, excess weight loss, and laboratory tests including fasting blood sugar (FBS), lipid profile, serum iron (Fe), ferritin, total iron-binding capacity (TIBC), 25-OH vitamin D, vitamin B12, liver function tests, and albumin were recorded preoperatively and within 3: and 6-month follow-up.

Results

Weight loss and BMI reduction was significantly more in patients with higher BMI level (P=0.007), and excess weight loss was higher in patients with lower preoperative BMI level (P=0.007), and excess weight loss was higher in patients with lower preoperative BMI level (P=0.007), and excess weight loss was higher in patients with lower preoperative BMI level (

Conclusion

Based on this study, 180-cm intestinal bypassed length works for patients with a BMI level of 40 to 45 and 45 to 50 kg/m2, according to their significant decrease in weight, BMI, and improving glycolipid profile.

Read the full paper

1. Introduction

Obesity is among the newest health matters that human beings are struggling with today. This condition is increasingly developing in both developed and developing countries. Urbanization, sedentary lifestyle, and dietary changes are factors that have led to a growing rate of obesity [1].

Obesity has a variety of complications causing lower life expectancy including metabolic syndrome, hypertension, insulin resistance, type-2 diabetes mellitus, cardiovascular diseases, osteoarthritis, low back pain, and increased risk of malignancy. In addition, obese people are struggling with decreased self-esteem as they are not satisfied of their appearance leading to depression and reluctance of participation in social activities [2Not reported5].

Bariatric surgery is the most effective treatment for severe obesity. This surgical procedure causes persistent weight loss, modulates complications of obesity, and increases quality of life and eventually patients' life expectancy [6].

Variety of bariatric surgeries are being performed now. Perhaps, the most popular one is Roux-en-Y gastric bypass (RYGB). Recently, it has been confirmed that the laparoscopic mini-gastric bypass/one anastomosis gastric bypass (MGB/OAGB) as an easier technique of gastric bypass is even more effective than the classic technique, RYGB [7, 8]. The RYGB has two limbs: alimentary or Roux limb and biliopancreatic limb. The MGB/OAGB has only one gastrojejunal anastomosis, which is called the biliopancreatic limb as well.

Previous studies in the RYGB field have presented that increased length of the biliopancreatic arm instead of the alimentary limb can lead to more weight reduction [9]. On the contrary, studies have shown that the total small intestine length is different in patients and biliopancreatic limb length is important to avoid complications such as malabsorption or malnutrition and to achieve more weight loss postoperatively [8Not reported10]. In this term, different studies have assessed various lengths of the biliopancreatic arm based on small intestine length or patients' body mass index (BMI).

Although studies have presented valuable results, their presentations are controversial and researchers have not declared unanimous results [11Not reported14].

Based on the importance of selecting the best technique of gastric bypass surgery, preventing secondary malabsorption and metabolic complications, and due to controversial findings of previous studies, we aimed to assess short-term metabolic and nutritional effect of MGB/OAGB with 180-centimeter (cm) intestinal bypass length in patients with a BMI of 40 to 45 and 45 to 50 kg/m2.

2. Methods and Materials

This is a prospective cross-sectional study based on 50 patients admitted to our university hospital for MGB/OAGB in 2016 to 18. Approximately, 300 total bariatric surgeries are performed in our center every year, from which, 50% of them are MGB/OAGB surgery.

Inclusion criteria were age between 25 and 65 years with BMI ≥40 kg/m2 without any obesity-related comorbidities (e.g., diabetes mellitus, hypertension, and obstructive sleep apnea), consent declaration for participation in this study, patients' ability to tolerate laparoscopic surgery, and lack of laparotomy history.

Exclusion criteria were previous history of any bariatric surgery (e.g., gastric banding, balloon gastroplasty, or other methods), patients' unwillingness or decision change not to participate in the study, having any positive medical history for gastroesophageal reflux disease, diabetes mellitus, hypertension, thyroid, respiratory, kidney, and liver failure, and failure to follow recommended diet supplementation after MGB/OAGB.

Consent forms for participating and all-needed information about the study were given to patients prior to the surgery. This study was conducted after receiving its approval from medical ethics in the research department of our university (registration number: IR.MUI.MED.REC.1398.131).

From our extensive referral for bariatric surgery and after reviewing inclusion and exclusion criteria for all of the patients, we included 50 patients for this research. All patients were allocated into two groups according to their preoperative BMI (40 to 45 and 45 to 50 kg/m2). All patients were supposed to undergo MGB/OAGB with an intestine length bypass of 180 cm [14]. 25 patients were put in group 1 (40 to 45 kg/m2), and 25 patients were put in group 2 (45 to 50 kg/m2).

Essential demographic information including gender, height, first BMI, and laboratory results including fasting blood sugar (FBS), triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), serum iron (Fe), ferritin, total iron-binding capacity (TIBC), 25-OH vitamin D, vitamin B12, international normalized ratio (INR), albumin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were obtained preoperatively. Weight loss, BMI, and abovementioned laboratory data were reassessed in 15, 30, 90, and 180 days postoperatively.

All data were analyzed using IBM SPSS version 23.0 (Chicago, United States). Qualitative variables are expressed as number of patients and percentages. Quantitative variables are expressed as mean and standard deviation (SD). The Kolmogorov: Smirnov test was used to check the normal distribution of the variables. If they were normally distributed, the t-test and chi-square were used and if not, the Mann: Whitney and Wilcoxon tests were used. ANOVA and ANOVA with repeated measures were used to compare the results of each variable between more than two groups. P value <0.05 was considered significant.

2.1. Surgical Protocol

Under general anesthesia, the patient was put in the supine leg splitting position. A nasogastric tube and Foley catheter were inserted. A 150-millimeter (mm) Veress needle was placed in the left subcostal location, and pneumoperitoneum was established using carbon dioxide (CO2) to a maximum pressure of 15 millimeter mercury (mmHg). An 11-mm optical viewing trocar was inserted 15 to 20 cm below the xiphoid process to the left of the midline. The other laparoscopic ports were inserted under direct vision.

The 12-mm right-handed working port was placed in the left midclavicular line, while the 5-mm left-handed working port was placed in the right midclavicular line. One 5-mm port was placed in the epigastrium for retracting the left lobe of the liver. Another 5-mm port was inserted in the left anterior axillary line at the level of the camera port. A narrow and long, approximately, 30 to 40 milliliter (ml) gastric pouch was created just below the crow's foot over a 32 French orogastric tube by four or five 60-mm Endo-GIA Tristaple purple loads (Covidien®/Medtronic).

The gastrojejunostomy anastomosis was created 180 cm from the Treitz ligament with one 45-mm Endo-GIA Tristaple purple load (Covidien®/Medtronic) and was sutured with 2/0 Prolene twice to make sure there will not be any leak from the anastomosis site. After the surgery, all of the patients were sent to the recovery room and when they become conscious, they were sent to the surgery ward. All of the patients were discharged after 2 days of hospitalization if they did not face any early postoperative complications (e.g., peritonitis, leak from the anastomosis, bleeding, and surgical site infection.).

We put all of our patients on full supplementation protocol as follows: first month, daily 10 ml of Sanostol® multivitamin syrup, and after that, until one year after the surgery, we recommended daily Pharmaton® multivitamin capsules.

3. Results

Our patients' mean age was 45 ± 8.36 years (range: 36 to 55) in group 1 and 46 ± 5.49 years in group 2 (range: 35 to 58) (P=0.15). 24% and 40% of groups 1 and 2 were male, respectively (P=0.22). Mean height of group 1 was 165.44 ± 4.98 cm (range: 150 to 175) and for the other group was 165.64 ± 8.45 cm (range: 150 to 175) (P=0.58). Table 1 presents patients' body weight, BMI, and excess weight loss (EWL) in different phases following MGB/OAGB.

Based on Table 1, all mentioned variables changed significantly in the two groups. Patients in groups 1 and 2 achieved %EWL of 60.51% and 46.64% after 6 months, respectively.

Table 2 presents laboratory factors and their changes in 3-month and 6-month periods after the surgery. As it can be seen that FBS, TG, TC, LDL, AST, and ALT have a down slope trend, which statistics showed significant changes in some of them; however, other factors like iron, ferritin, vitamin D, and vitamin B12 had been decreased at first and increased afterwards and none of them were significant statistically. None of our patients faced early postoperative complications. During the 6-month follow-up, none of our patients needed hospital admission for late complications or any reoperations.

All of the data will be available for secondary analysis in necessary cases from the corresponding author through email address.

4. Discussion

Bariatric surgery as the absolute method of achieving weight loss in those with severe obesity is the favorable procedure used by surgeons. In this matter, a variety of techniques and their debatable concepts have been reviewed and studied to find the best technique of surgery to obtain the best outcomes and the least adverse effects [15].

The other issue about bariatric surgery is the intestinal bypassed length that causes fewer complications such as malabsorption and also acceptable weight loss. Studies have recommended different formulas for that [12Not reported16].

In the current study, we aimed to compare whether more obese patients need longer intestinal bypass length or 180 cm which is a widely used and confirmed intestinal bypass length that works for them too according to their nutritional, metabolic, and weight loss changes following MGB/OAGB. Thus, two comparable groups with a BMI of 40 to 45 and 45 to 50 kg/m2 each containing 25 cases were compared from baseline.

Based on our findings, both groups lost their weight, BMI, and excess weight significantly. According to graphs' slope of these weight-associated variables, both groups had the same slope angle although group 2 had a higher starting point, but as our results showed, both groups had successful and progressive trend in their weight and BMI loss. As it can be seen in Table 1, after 6 months, both groups achieved BMI <35 kg/m2. However, %EWL was higher in patients with lower preoperative BMI level and it can be explained through the EWL formula and its instinct, and patients with higher BMI had more weight to lose in a specific amount of time; therefore, using this indicator is not representative of all changes in weight correctly and completely.

Group 1 patients achieved a mean %EWL of 60.51% 6 months after the surgery; however, group 2, which had higher BMI and higher excess weight, achieved losing 46.64% of their weight during this time by the 180 cm intestinal anastomosis.

In a study conducted by Mahawar et al., they presented that a bypass length of 100 to 200 cm has acceptable outcomes and few possible complications such as malabsorption [16], while in a study conducted by Carbajo et al., they assessed patients who had undergone MGB/OAGB with 250 to 300 cm bypass length and found malabsorption in 1.1% of them that was compatible with prevalence of protein malabsorption presented in other studies [14]. In a study conducted by Lee et al., they compared outcomes of MBG/OAGB surgery in which bypassed length was chosen based on patients' BMI.

In their study, bypassed limb was 150 cm, 250 cm, and 350 cm for those with a BMI of less than 40, 40 to 50, and over 50 kg/m2, respectively. BMI reduction in their patients were 10.7, 15.5, and 23.3, respectively. In general, they concluded that decision on length of the limb should be made based on BMI. In addition, they presented that for those with lower BMI, choosing the appropriate limb length is more serious [13].

Other variables including metabolic and nutritional factors were assessed among two groups as well with intervals of three and six months after the surgery. In general, based on Table 2, we found that metabolic factors tend to change in an acceptable manner, such as decrease of TG, TC, LDL, FBS, and liver enzymes. It is reasonable that patients with higher BMI have higher levels of TG, TC, LDL, and FBS at the baseline, but both groups had progressive declined slope.

Bariatric surgeries reported controversial results on levels of liver enzymes, in which some of them mentioned these surgeries can deteriorate the liver function; however, others suggested that as the weight decreases, the grade of fatty liver decreases and they can cause improvement in the liver function tests. According to the baseline levels, other factors including HDL, serum iron, ferritin, vitamin D, and vitamin B12 were simultaneously decreased in 3 months and then increased after 6 months, and they could be due to postoperative supplement use.

Those changes were not statistically significant between both groups. It should be noted that HDL, which is the antiatherosclerotic lipid, was decreased after the surgery and it is an unexplained, unusual, and unfavorable change, which needed further evaluations.

The study by Rutledge and Walsh presented that gastric ulcer and iron deficiency anemia were the most prevalent and significant postoperative complications in their patients [17]. In our study, serum iron, ferritin, and vitamin B12, which are important indicators of intestinal absorption, were changed in the same way all together after 3 and 6 months.

The other study conducted by Lee et al. assessed serum glucose changes among obese people with type-2 diabetes mellitus. They found that patients with lower BMI had significantly lower liver enzymes and C-peptide preoperatively. In addition, they found that patients lipid profile and FBS returned to normal ranges in approximately 90% of the patients, but these changes were not significantly different among those with a BMI of less than 35 or more than 35 kg/m2 [18].

In a study in 2015, sleeve gastrectomy was compared with MGB/OAGB regarding lipid profile. They presented that although in 3: and 6-month follow-up, lipid profile changes to normal ranges were higher in MBG/OAGB, but after one year, both techniques had similar outcomes [19]. Other studies in this regard have assessed other techniques of bariatric surgery except MGB/OAGB, but outcomes of all studies are unanimous about positive effects of bariatric surgery on the glycolipid profile. In addition, most of the studies are in favor of bypass techniques in comparison to techniques with restrictive approach (e.g., sleeve gastrectomy) [20Not reported22].

To resolve our limitations, we suggest researchers to evaluate each single anastomosis length between two different groups of patients and different intestinal bypass length for patients with the same BMI to reach to a consensus for choosing appropriate intestinal bypass length for patients with different BMI category. Furthermore, larger sample size, randomized controlled trials, and longer postoperative follow-up can decrease the biases of choosing the patients and evaluating the results of bariatric surgery in the long term.

5. Conclusions

We found that 180-cm intestinal bypass length can make significant changes in weight and BMI in both groups of patients. Glycolipid changes were acceptable in both groups.

Acknowledgments

The authors send their gratitude toward Mr. Amir Salar Moazen Safaei for his kind support throughout this article.

Data Availability

All of the data will be available for secondary analysis in necessary cases from the corresponding author upon request through email.

Disclosure

The abstract of this study was presented in the 24th International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Congress held in Madrid, Spain.

Conflicts of Interest

The authors declare no potential conflicts of interest.

1 Malik V. S. Willett W. C. Hu F. B. Global obesity: trends, risk factors and policy implications Nature Reviews Endocrinology 2013 9 1 13 27 10.1038/nrendo.2012.199 2-s2.0-84871090162 23165161
2 Guh D. P. Zhang W. Bansback N. Amarsi Z. Birmingham C. L. Anis A. H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis BMC Public Health 2009 9 1 p. 88 10.1186/1471-2458-9-88 2-s2.0-64649083354 PMC2667420 19320986
3 Luppino F. S. de Wit L. M. Bouvy P. F. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies Archives of General Psychiatry 2010 67 3 220 229 10.1001/archgenpsychiatry.2010.2 2-s2.0-77649217019 20194822
4 Ungefroren H. Gieseler F. Fliedner S. Lehnert H. Obesity and cancer Hormone Molecular Biology and Clinical Investigation 2015 21 1 5 15 10.1515/hmbci-2014-0046 2-s2.0-84928649857 25719336
5 Fiori C. Z. Martinez D. Carissimi A. Obesity and Comorbidities. Mechanical Ventilation in the Critically Ill Obese Patient 2018 Berlin, GermanySpringer
6 Buchwald H. Avidor Y. Braunwald E. Bariatric surgery: a systematic review and meta-analysis JAMA 2004 292 14 1724 1737 10.1001/jama.292.14.1724 2-s2.0-5044242948 15479938
7 Rutledge R. The mini-gastric bypass: experience with the first 1,274 cases Obesity Surgery 2001 11 3 276 280 10.1381/096089201321336584 2-s2.0-0034974161 11433900
8 Lee W.-J. Ser K.-H. Lee Y.-C. Tsou J.-J. Chen S.-C. Chen J.-C. Laparoscopic Roux-en-Y vs. mini-gastric bypass for the treatment of morbid obesity: a 10-year experience Obesity Surgery 2012 22 12 1827 1834 10.1007/s11695-012-0726-9 2-s2.0-84878844865 23011462
9 Nergaard B. J. Leifsson B. G. Hedenbro J. Gislason H. Gastric bypass with long alimentary limb or long pancreato-biliary limb-long-term results on weight loss, resolution of co-morbidities and metabolic parameters Obesity Surgery 2014 24 10 1595 1602 10.1007/s11695-014-1245-7 2-s2.0-84937563777 24744188 PMC4153949
10 Musella M. Susa A. Greco F. The laparoscopic mini-gastric bypass: the Italian experience: outcomes from 974 consecutive cases in a multicenter review Surgical Endoscopy 2014 28 1 156 163 10.1007/s00464-013-3141-y 2-s2.0-84892986882 23982648
11 Noun R. Skaff J. Riachi E. Daher R. Antoun N. A. Nasr M. One thousand consecutive mini-gastric bypass: short: and long-term outcome Obesity Surgery 2012 22 5 697 703 10.1007/s11695-012-0618-z 2-s2.0-84862652753 22411569
12 Noun R. Zeidan S. Riachi E. Abboud B. Chalhoub V. Yazigi A. Mini-gastric bypass for revision of failed primary restrictive procedures: a valuable option Obesity Surgery 2007 17 5 684 688 10.1007/s11695-007-9119-x 2-s2.0-34250628447 17658031
13 Lee W.-J. Wang W. Lee Y.-C. Huang M.-T. Ser K.-H. Chen J.-C. Laparoscopic mini-gastric bypass: experience with tailored bypass limb according to body weight Obesity Surgery 2008 18 3 294 299 10.1007/s11695-007-9367-9 2-s2.0-40049107425 18193178
14 Carbajo M. A. Luque-de-León E. Jiménez J. M. Ortiz-de-Solórzano J. Pérez-Miranda M. Castro-Alija M. J. Laparoscopic one-anastomosis gastric bypass: technique, results, and long-term follow-up in 1200 patients Obesity Surgery 2017 27 5 1153 1167 10.1007/s11695-016-2428-1 2-s2.0-84992364305 27783366 PMC5403902
15 Parmar C. D. Mahawar K. K. One anastomosis (mini) gastric bypass is now an established bariatric procedure: a systematic review of 12,807 patients Obesity Surgery 2018 28 9 2956 2967 10.1007/s11695-018-3382-x 2-s2.0-85049694828 29995293
16 Mahawar K. K. Kumar P. Parmar C. Small bowel limb lengths and Roux-en-Y gastric bypass: a systematic review Obesity Surgery 2016 26 3 660 671 10.1007/s11695-016-2050-2 2-s2.0-84959129386 26749410
17 Rutledge R. Walsh T. R. Continued excellent results with the mini-gastric bypass: six-year study in 2,410 patients Obesity Surgery 2005 15 9 1304 1308 10.1381/096089205774512663 2-s2.0-27644494724 16259892
18 Lee W.-J. Wang W. Lee Y.-C. Huang M.-T. Ser K.-H. Chen J.-C. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI >35 and <35 kg/m2 Journal of Gastrointestinal Surgery 2008 12 5 945 952 10.1007/s11605-007-0319-4 2-s2.0-42449092032 17940829
19 Milone M. Lupoli R. Maietta P. Lipid profile changes in patients undergoing bariatric surgery: a comparative study between sleeve gastrectomy and mini-gastric bypass International Journal of Surgery 2015 14 28 32 10.1016/j.ijsu.2014.12.025 2-s2.0-84922783890 25576760
20 Vix M. Diana M. Liu K.-H. Evolution of glycolipid profile after sleeve gastrectomy vs. Roux-en-Y gastric bypass: results of a prospective randomized clinical trial Obesity Surgery 2013 23 5 613 621 10.1007/s11695-012-0827-5 2-s2.0-84876471202 23207829
21 Benaiges D. On behalf the Obemar Group Flores-Le-Roux J. A. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile Obesity Surgery 2012 22 8 1268 1275 10.1007/s11695-012-0662-8 2-s2.0-84864877955 22544352
22 Yang X. Yang G. Wang W. Chen G. Yang H. A meta-analysis: to compare the clinical results between gastric bypass and sleeve gastrectomy for the obese patients Obesity Surgery 2013 23 7 1001 1010 10.1007/s11695-013-0938-7 2-s2.0-84878867088 23595210
Table 1

Weight, BMI, and excess weight loss changes trend following 6: month follow-up after the laparoscopic one anastomosis gastric bypass.

VariablesBMI groups (kg/m2)Baseline15 days30 days3 months6 months P 1 value P 2 value
Weight, kg (mean ± SD)40 to 45 (n = 25)113.80 ± 8.65106.88 ± 9.02101.72 ± 7.9291.20 ± 8.2081.04 ± 7.71<0.0010.001
45 to 50 (n = 25)132.56 ± 11.86125.68 ± 10.11120.64 ± 9.88109.72 ± 11.4395.96 ± 11.53<0.001
BMI, kg/m2 (mean ± SD)40 to 45 (n = 25)41.53 ± 1.4437.50 ± 7.1637.15 ± 1.6433.25 ± 1.9429.44 ± 2.42<0.0010.007
45 to 50 (n = 25)48.36 ± 2.2845.88 ± 2.4844.03 ± 2.2639.96 ± 2.2234.89 ± 1.82<0.001
Excess weight loss (%)40 to 45 (n = 25)Not reported14.79 ± 4.7923.04 ± 5.7344.24 ± 12.9260.51 ± 24.26<0.0010.007
45 to 50 (n = 25)Not reported10.77 ± 4.1115.45 ± 6.0629.12 ± 15.2246.64 ± 19.04<0.001

P 1 value is the mean differences of each variable in each group data during the time and was calculated using ANOVA with repeated measures. P2 value is the comparison of both the groups for each variable in multiple measures and was calculated with ANOVA.

Table 2

Metabolic and nutritional state results of each BMI group from baseline to 6 months after the laparoscopic one anastomosis gastric bypass.

Variables (mean ± SD)BMI groups (kg/m2)Normal laboratory reference rangeBaseline (n = 50)3 months (n = 50)6 months (n = 50) P 1 value P 2 value
TG (mg/dL)40 to 4535 to 200127.72 ± 51.58119.32 ± 39.13103.92 ± 42.797<0.0010.02∗
45 to 50183.00 ± 71.44162.80 ± 68.30137.88 ± 65.63<0.001
TC (mg/dL)40 to 45Normal: <200
Borderline: 200 to 240
High risk: 240 to 400
Very high risk: >400
181.36 ± 37.50160.24 ± 33.69150.84 ± 22.99<0.0010.03∗
45 to 50209.08 ± 42.75174.04 ± 21.13156.60 ± 21.90<0.001
HDL (mg/dL)40 to 45Men: >35
Women: >45
Desirable value: 40 to 60
Protect against CHD: >60
High risk for CHD: <20
47.32 ± 9.7742.80 ± 5.1744.40 ± 7.460.920.14
45 to 5054.08 ± 14.3249.16 ± 10.5245.52 ± 6.130.73
LDL (mg/dL)40 to 45Desirable: <130
Borderline: 130 to 160
High risk: >160
108.28 ± 32.4699.32 ± 21.3992.52 ± 16.870.440.59
45 to 50117.20 ± 25.46109.64 ± 14.6997.60 ± 14.500.29
Fe (mcg/dL)40 to 4560 to 15087.88 ± 8.8577.48 ± 21.7581.64 ± 30.130.950.40
45 to 5092.08 ± 15.3481.36 ± 12.4189.08 ± 18.090.12
Ferritin (ng/mL)40 to 4520 to 20065.20 ± 15.9757.64 ± 26.6659.20 ± 17.840.700.13
45 to 5065.08 ± 20.8862.18 ± 23.2964.68 ± 48.860.47
TIBC (mcg/dL)40 to 45240 to 450257.76 ± 52.26292.2 ± 47.57304.56 ± 52.390.150.054
45 to 50280.88 ± 75.94285.92 ± 65.66298.40 ± 75.310.55
Vit B12 (pg/mL)40 to 45200 to 900349.64 ± 112.06342.68 ± 126.76354.52 ± 107.180.440.03∗
45 to 50300.56 ± 63.82310.52 ± 71.25308.60 ± 63.680.53
Vit D (ng/mL)40 to 45Severe deficient: <10
Deficient: 10 to 30
Optimal level: 31 to 80
High normal: 91 to 99
Overdose: 100 to 150
Toxic: >150
40.20 ± 4.9336.77 ± 5.8937.80 ± 6.300.570.99
45 to 5038.13 ± 3.8835.82 ± 6.5035.78 ± 9.860.64
FBS (mg/dL)40 to 45Normal: <100
Prediabetes: 100 to 125
Diabetes: >125
96.60 ± 10.4285.72 ± 8.4482.12 ± 6.610.02∗0.21
45 to 50103.72 ± 15.6593.56 ± 11.4184.76 ± 7.940.03∗
INR40 to 45<1.51.08 ± 0.111.10 ± 0.071.11 ± 0.060.430.53
45 to 501.14 ± 0.141.12 ± 0.111.14 ± 0.090.33
Alb (g/dL)40 to 453.5 to 5.54.47 ± 0.244.35 ± 0.314.29 ± 0.280.940.69
45 to 504.54 ± 0.204.40 ± 0.194.31 ± 0.190.72
AST (IU/L)40 to 45<4021.48 ± 5.3518.28 ± 3.3116.84 ± 3.140.600.61
45 to 5023.16 ± 5.2419.64 ± 2.9718.16 ± 3.680.57
ALT (IU/L)40 to 45Male: <40
Female: <30
25.60 ± 6.8220.00 ± 4.9716.92 ± 3.660.430.39
45 to 5025.56 ± 8.6420.88 ± 5.3418.72 ± 4.050.38
ALP (IU/L)40 to 45Female: 64 to 306
Male: 80 to 306
198.28 ± 18.32192.20 ± 17.40194.64 ± 17.920.290.47
45 to 50187.20 ± 27.43184.04 ± 26.81195.24 ± 19.530.66

TG, triglyceride; HDL, high-density lipoprotein; CHD, coronary high disease; LDL, low-density lipoprotein; TC, total cholesterol, Fe, iron; TIBC, total iron-binding capacity; Vit, vitamin; FBS, fasting blood glucose; INR, international normalized ratio; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; g: gram; mg: milligrams; ng: nanograms; mcg: micrograms; pg: picograms; L: liter; dL: deciliter; mL: milliliter; IU: international unit. P1 value is the mean differences of each variable in each group data during the time and was calculated using ANOVA with repeated measures. P2 value is the comparison of both the groups for each variable in multiple measures and was calculated with ANOVA. ∗Indicates significant P value.

Publication and source details

Original title: The Early Results of the Laparoscopic Mini-Gastric Bypass/One Anastomosis Gastric Bypass on Patients with Different Body Mass Index

Mohsen Mahmoudieh; Behrouz Keleidari; Naser Afshin; Masoud Sayadi Shahraki; Shahab Shahabi Shahmiri; Erfan Sheikhbahaei; Hamid Melali

Journal of Obesity · 2020

Academic Editor: Mario Musella

Copyright © 2020 Mohsen Mahmoudieh et al.2020https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T17:54:27.842216+00:00

DOI: 10.1155/2020/7572153 · PMC7091541